Navigation Links
Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation
Date:4/21/2009

ts of $150.0 million related to the Phenomix and Pierre Fabre collaboration agreements. This compares to last fiscal year spending of $671.0 million, including development milestone expenses of $51.0 million and total license payments of $180.0 million related to Ironwood Pharmaceuticals and Novexel collaboration agreements. Excluding the impact of the license agreement payments, research and development expense increased 4.2%.

Income tax expense was $202.8 million, reflecting a full-year effective tax rate of 20.9%. Reported net income for the fiscal year ended March 31, 2009 decreased 20.7% to $767.7 million from net income of $968.0 million reported in the prior fiscal year. Reported diluted earnings per share for the fiscal year totaled $2.52 per share as compared to reported earnings per share of $3.06 in fiscal 2008. Excluding the licensing payments made to Phenomix and Pierre Fabre, the Azor termination fee and the charge taken related to the USAO investigation, adjusted non-GAAP net income and earnings per share for the fiscal year ended March 31, 2009 would be $1,052.4 million, or $3.46 per diluted share, compared to $1,124.1 million, or $3.56 per diluted share in the prior fiscal year. During fiscal year 2009 the Company repurchased approximately 10.2 million shares under its currently authorized repurchase program. There is authorization to repurchase an additional 5.7 million shares under this program which has no expiration date.

Fiscal 2010 Guidance

Regarding the fiscal year ending March 31, 2010, the Company expects that diluted earnings per share will be in a range of $3.45 to $3.55, including planned research and development milestone payments related to existing pipeline products but not including any licensing or milestone payments which may be made for additional product development transactions or acquisitions that may occur during the fiscal year.

Key assumption
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013 ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale ... announced price reductions on their popular PhenObestin 37.5 non-prescription ... clients to lose weight as effortlessly as possible has ... more than 50%. , Bottles have been reduced from ... all orders will receive free shipping. , Made ...
(Date:5/24/2013)... you start the grill, before you watch the game, kick back ... Kotb on the Today Show on Memorial Day. Carley Knobloch, ... and Hoda, including the new LawnBott® LB75 robotic mower. ... military who made the ultimate sacrifice for us. On Memorial ... family and enjoy the day. With a LawnBott® robotic mower, ...
(Date:5/24/2013)... (HealthDay News) -- Patients hospitalized for heart failure appear ... on Mondays or in the morning, a new study ... highest among heart failure patients admitted in January, on ... scheduled to present their findings Saturday in Portugal at ... the European Society of Cardiology. "The fact ...
(Date:5/24/2013)... RI (PRWEB) May 24, 2013 With Memorial ... why Amica Insurance is offering tips to help ... National Fire Protection Association (NFPA) reports that gas ... 2006 and 2010. Charcoal or other solid-fueled grills, meanwhile, caused ... , As a result, Amica Insurance is sharing the following ...
(Date:5/24/2013)... Calif.) (PRWEB) May 24, 2013 ... House Appropriators and the California congressional delegation, joined ... restore sequestered industry user fees paid to the ... to ensure that future across-the-board cuts will not ... of the FY14 Agriculture, Rural Development and FDA ...
Breaking Medicine News(10 mins):Health News:ShopPharmacyCounter.com PhenObestin 37.5 Summer Sale Now On 2Health News:LawnBott® Visits the Today Show with Kathie Lee and Hoda 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3
... CHENGDU, China, May 20 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., ... of modernized traditional Chinese medicine ("TCM") based in,Chengdu, ... new distribution,agreements with a total of 15 regional ... Many of these agreements, which are for a ...
... iron therapies, SAN ANTONIO, May 20 Mission ... oral iron supplement for,treatment of iron deficiency anemia (IDA) ... depletion of stored iron that prevents maturation of red,blood ... as well as,essential vitamins and minerals to help patients ...
... Health IT Solutions Recognized, BOSTON, May 20 ... TEPR Awards honorees during the Opening Session of,the ... Conference in,Ft. Lauderdale, Florida., TEPR Awards annually ... and solutions. The 2008 TEPR Awards honorees,are:, ...
... for healthy women entering the menopause. , HRT in the ... the first few years of the menopause who need HRT ... This is the conclusion and clinical advice of the First ... on March 29th and 30th, 2008. , The Zrich Summit ...
... May 18, 2008 TAP Pharmaceutical Products ... studies evaluating investigational new drug TAK-390MR, the first proton ... technology, in healing patients with erosive esophagitis (EE) and ... at the Digestive Disease Week (DDW) annual meeting in ...
... Ratify E&Y and Approve Charter Amendment; ... Board Re-appoints Leadership, CHICAGO, May ... said today that its Board of Directors declared,a regular quarterly dividend ... stockholders of record on June 4, 2008. The dividend is the,second ...
Cached Medicine News:Health News:Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors 2Health News:Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors 3Health News:Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S. 2Health News:Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S. 3Health News:2008 TEPR Awards Honorees Announced 2Health News:Global menopause summit concludes HRT is safe for healthy women entering menopause 2Health News:Global menopause summit concludes HRT is safe for healthy women entering menopause 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 2Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 3Health News:TAK-390MR Phase 3 data presented at Digestive Disease Week 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5
(Date:5/24/2013)... May 24, 2013  An international roster of experts ... 18, in Santa Monica, Calif. , ... therapies for MPM, a rare form of cancer that ... pleura, the lining of the chest. Hosted ... Institute, the 3rd Annual International Symposium on Lung-Sparing Therapies ...
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... 24, 2013 In accordance with Rule 17.1 and ... of the United States Exchange Act, Echo Pharma Acquisition Limited ... Elan Corporation (NYSE: ELN). Background On ... an offer for the entire of the issued and to ... "Original Offer").  On 20 May 2013, Royalty ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... Masimo (Nasdaq: MASI ... showcasing Masimo noninvasive patient monitoring technologies were presented last ... Annual Meeting in San Diego, California.  The largest ... Meeting provides an important platform for previewing the latest ...
... Wash., Oct. 27 The International Foundation for ... announce the forthcoming release of the mSCAN (mobile ... (Sonography Clinical Assessment Notebook), was developed by IFSER ... for clinical assessment tools in sonography. Based on ...
Cached Medicine Technology:Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 2Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 3Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 4Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 5Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 6Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 7Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 8Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting 9IFSER: Introducing the mSCAN 2
... This antimicrobial skin cleanser will not leave ... with frequent washings. With persistent Antimicrobial action, ... of microorganisms, including gram-negative and gram-positive bacteria, ... as a 15 second hand wash. The ...
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... Povidone Iodine Prep Pads ... surface pathogens including bacteria, ... yeast. Povidone Iodine is ... wounds or mucus membranes. ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: